Materiały źródłowe

• #1 An Overview of Gaucher Disease

  https://www.mdpi.com/2075-4418/14/24/2840

  Gaucher disease is the most prevalent LSD, with an incidence of 1 case per 40,000–60,000 births in the general population; however, it can occur in 1–800 births within the Ashkenazi Jewish population. […] A meta-analysis by Wanh Meimei in 2023 reported a global prevalence of GD at 1.5 cases per 100,000 live births. […] The first records of Gaucher disease in Mexico were from 1966 at the Centro Médico Nacional “La Raza” of the Instituto Mexicano del Seguro Social (IMSS). […] By 2005, a general census identified 68 cases residing in the states of Sinaloa, Nuevo León, Michoacán, Morelos, Jalisco, Puebla, Baja California Sur, Coahuila, and Mexico City. […] In a cohort from 2021 including GD cases from México and Spain, type 1 GD was reported to be more common among the Mexican population. […] This disease is among the 20 rare diseases recognized in Mexico.

• #2 Monitoring | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/monitoring/

  Gaucher disease (GD) is a rare, autosomal recessive disorder.1 Although rare, it is the most common type of lysosomal storage disease.1 […] There are three types of GD. Type 1 Gaucher disease (GD1) is the most prevalent form of the disease, accounting for more than 90% of all cases.4 […] GD1 is a pan-ethnic condition, although it does have a higher prevalence in people of Ashkenazi Jewish ancestry.5 […] GD1 affects: 19 in 100,000 within the overall population12 […] ~1 in 600 within the Ashkenazi Jewish population3 […] ~1 in 17 within the Ashkenazi Jewish community that are carriers13 […] an estimated 6,000 individuals in the United States3,14 […] GD1 is genetic and has an autosomal recessive inheritance pattern.3 If both parents are carriers, there is a 50% chance of the child being a carrier, a 25% chance of them having Gaucher disease, and a 25% chance that they will not be affected.3

• #3 Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9821068/

  There is a need for a better understanding of the global incidence and prevalence of GD, together with an evaluation of incidence rates for specific ethnic populations found within each geographic region. […] The objective of this targeted review was to provide a qualitative synthesis of global GD incidence and prevalence estimates by region, overall, and by disease type, published in the last 10 years. […] GD incidence was poorly documented overall, and GD type-specific estimates for incidence and prevalence were rare. Few estimates were available for GD2 and GD3. […] The regional generalizability of prevalence estimates was considered adequate for North America, Europe, Latin America, and the Asia-Pacific region and intermediate for the Middle East (because no estimates were found for Egypt or Turkey, two of the four countries of the region with the largest population sizes). […] The synthesis of GD incidence and prevalence estimates by region in this review highlighted significant data gaps.

• #4 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #5

  https://journals.lww.com/jpho-online/fulltext/2023/05000/global_epidemiology_of_gaucher_disease__an_updated.3.aspx

  Gaucher disease [GD], an autosomal recessive lysosomal storage disorder, is characterized by progressive lysosomal storage of glucocerebroside in macrophages predominantly in bone, bone marrow, liver, and spleen. Meta-analysis of global GD epidemiology was not available before this study. […] To provide a systematic review and meta-analysis of birth prevalence and prevalence of GD in multiple countries. […] The global birth prevalence of GD was 1.5 cases [95% confidence interval: 1.0 to 2.0] per 100,000 live births. The global prevalence of GD was 0.9 cases [95% confidence interval: 0.7 to 1.1] per 100,000 inhabitants. […] This is the first comprehensive systematic review that presented quantitative data of GD global epidemiology. Quantitative data on global epidemiology of GD could be the fundamental to evaluate the global efforts on building a better world for GD patients.

• #6

  https://journals.lww.com/jpho-online/fulltext/2023/05000/global_epidemiology_of_gaucher_disease__an_updated.3.aspx

  Birth prevalence data of GD were extracted from 16 studies and covered 14 areas/countries. The global birth prevalence of GD was 1.5 cases (95% confidence interval [CI]: 1.0 to 2.0) per 100,000 live births. […] Prevalence data of GD were extracted from 4 studies and covered 3 areas/countries. The global prevalence of GD was 0.9 cases [95% CI: 0.7 to 1.1] per 100,000 inhabitants. […] To our best knowledge, this is the first systematic review to present quantitative data of GD global epidemiology. Quantitative GD global epidemiology is the fundamental to evaluate the global efforts that build a better world for GD patients.

• #7

  https://journals.lww.com/jpho-online/fulltext/2023/05000/global_epidemiology_of_gaucher_disease__an_updated.3.aspx

  Gaucher disease [GD], an autosomal recessive lysosomal storage disorder, is characterized by progressive lysosomal storage of glucocerebroside in macrophages predominantly in bone, bone marrow, liver, and spleen. Meta-analysis of global GD epidemiology was not available before this study. […] To provide a systematic review and meta-analysis of birth prevalence and prevalence of GD in multiple countries. […] The global birth prevalence of GD was 1.5 cases [95% confidence interval: 1.0 to 2.0] per 100,000 live births. The global prevalence of GD was 0.9 cases [95% confidence interval: 0.7 to 1.1] per 100,000 inhabitants. […] This is the first comprehensive systematic review that presented quantitative data of GD global epidemiology. Quantitative data on global epidemiology of GD could be the fundamental to evaluate the global efforts on building a better world for GD patients.

• #8

  https://journals.lww.com/jpho-online/fulltext/2023/05000/global_epidemiology_of_gaucher_disease__an_updated.3.aspx

  Birth prevalence data of GD were extracted from 16 studies and covered 14 areas/countries. The global birth prevalence of GD was 1.5 cases (95% confidence interval [CI]: 1.0 to 2.0) per 100,000 live births. […] Prevalence data of GD were extracted from 4 studies and covered 3 areas/countries. The global prevalence of GD was 0.9 cases [95% CI: 0.7 to 1.1] per 100,000 inhabitants. […] To our best knowledge, this is the first systematic review to present quantitative data of GD global epidemiology. Quantitative GD global epidemiology is the fundamental to evaluate the global efforts that build a better world for GD patients.

• #9 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #10 How Many People Have Gaucher Disease?

  https://www.healthline.com/health/how-common-is-gaucher-disease

  Type 2 and 3 Gaucher disease are estimated to occur in 1 in 100,000-300,000 live births. […] Gaucher disease is most common in people of Ashkenazi Jewish descent, a group of Jewish people who traditionally lived in Eastern and Central Europe. […] About 6% of people in this ethnic group carry a gene for Gaucher disease, and about 1 in 855 develop it.

• #11 Gaucher Disease: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/944157-overview

  Mortality and morbidity varies with the different types. Type 1 Gaucher disease may present in childhood with hepatosplenomegaly, pancytopenia, and skeletal disease, although there is striking clinical variability in disease severity. Prior to the advent of treatment, bleeding and hepatic complications were more common, and patients with severe splenomegaly would routinely undergo splenectomy and have severe, sometimes fatal, bleeding complications. This risk has been dramatically reduced with the development of enzyme replacement therapy (ERT). Bone disease was a common cause of morbidity but is seen less frequently in treated patients. […] All forms of Gaucher disease are panethnic. Type 1 Gaucher disease is one of the most common lysosomal storage diseases and is the most prevalent genetic disorder in individuals of Ashkenazi Jewish descent. Type 3 disease is more common in the Norrbottnian region of Sweden and parts of Asia.

• #12 Gaucher disease: MedlinePlus GeneticsLock

  https://medlineplus.gov/genetics/condition/gaucher-disease/

  Gaucher disease occurs in 1 in 50,000 to 100,000 people in the general population. Type 1 is the most common form of the disorder in Europe, Israel, Canada, and the United States. This form occurs more frequently in people of Ashkenazi (eastern and central European) Jewish heritage than in those with other backgrounds; it affects 1 in 500 to 1,000 people of Ashkenazi Jewish heritage. Types 2 and 3 are uncommon and do not occur more frequently in people of Ashkenazi Jewish descent. These types can be more prevalent than type 1 in certain regions, such as Egypt, India, Japan, Poland, and Sweden.

• #13 Gaucher Disease (GD) | Takeda U.S. Medical

  https://www.takedamedconnect.com/diseases-and-conditions/rare-metabolic/gaucher-disease

  Gaucher disease is a rare disease with a frequency of about 1 in 50,000 to 1 in 100,000 worldwide, but its particularly more common in the Ashkenazi Jewish population (1 in 800 to 1 in 1,000). Due to its inheritance pattern, it tends to affect males and females equally. The onset of symptoms can vary depending on disease type and severity with milder forms presenting in adulthood and a significant number of individuals with type 1 never receiving any medical attention. […] GD is generally categorized into 3 types: type 1 is the most prevalent, accounting for more than 90% of all cases, and is characterized by the presence of bone disease and the lack of neurologic features. Type 2 and Type 3 both typically involve neurodegeneration.

• #14 Gaucher disease: MedlinePlus GeneticsLock

  https://medlineplus.gov/genetics/condition/gaucher-disease/

  Gaucher disease occurs in 1 in 50,000 to 100,000 people in the general population. Type 1 is the most common form of the disorder in Europe, Israel, Canada, and the United States. This form occurs more frequently in people of Ashkenazi (eastern and central European) Jewish heritage than in those with other backgrounds; it affects 1 in 500 to 1,000 people of Ashkenazi Jewish heritage. Types 2 and 3 are uncommon and do not occur more frequently in people of Ashkenazi Jewish descent. These types can be more prevalent than type 1 in certain regions, such as Egypt, India, Japan, Poland, and Sweden.

• #15 What Is Gaucher Disease? | National Gaucher Foundation

  https://www.gaucherdisease.org/about-gaucher-disease/what-is/

  Gaucher disease affects up to 1 in 40,000 live births in the general population. […] Gaucher disease is more common among Jews of Ashkenazi (Eastern European) descent, occurring in approximately 1 in 450 within this population. As many as 1 in 10 may carry the mutated gene responsible for Gaucher disease.

• #16 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #17 Monitoring | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/monitoring/

  Gaucher disease (GD) is a rare, autosomal recessive disorder.1 Although rare, it is the most common type of lysosomal storage disease.1 […] There are three types of GD. Type 1 Gaucher disease (GD1) is the most prevalent form of the disease, accounting for more than 90% of all cases.4 […] GD1 is a pan-ethnic condition, although it does have a higher prevalence in people of Ashkenazi Jewish ancestry.5 […] GD1 affects: 19 in 100,000 within the overall population12 […] ~1 in 600 within the Ashkenazi Jewish population3 […] ~1 in 17 within the Ashkenazi Jewish community that are carriers13 […] an estimated 6,000 individuals in the United States3,14 […] GD1 is genetic and has an autosomal recessive inheritance pattern.3 If both parents are carriers, there is a 50% chance of the child being a carrier, a 25% chance of them having Gaucher disease, and a 25% chance that they will not be affected.3

• #18 Population-based cohort of 500 patients with Gaucher disease in Israel | BMJ Open

  https://bmjopen.bmj.com/content/9/1/e024251

  A total of 500 patients with GD were identified and assessed. […] The incidence of GD in Ashkenazi Jews, the majority of whom reside in Israel, is linked with a high carrier frequency of the mutation N370S of 1 in 17.5 and a disease prevalence of 1 in 850. […] Establishing a population-based cohort of patients with GD is essential to understanding disease progression and management. […] The goal of this study was to characterise a population-based cohort of patients with GD relative to the general population and describe sociodemographic and clinical characteristics by disease severity, as indicated by ERT use. […] The age-standardised prevalence of GD was 11.6 (95% CI 11.0 to 12.1) per 100000. […] The prevalence of GD found in this study is 10-fold higher than reported rates worldwide. […] Among patients with GD, we report an ERT treatment prevalence of 41.2%. […] These findings highlight the need for physicians to monitor patients with GD regardless of their ERT status.

• #19 Gaucher Disease – Pediatrics – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/pediatrics/inherited-disorders-of-metabolism/gaucher-disease

  There are 3 types of Gaucher disease, which vary in epidemiology, enzyme activity, and manifestations. […] People of Ashkenazi Jewish ancestry are at greatest risk; 1/12 is a carrier. […] Diagnosis of Gaucher disease is by DNA analysis and/or enzyme analysis of white blood cells; carriers are detected, and types are distinguished by mutation analysis.

• #20 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #21 Monitoring | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/monitoring/

  Gaucher disease (GD) is a rare, autosomal recessive disorder.1 Although rare, it is the most common type of lysosomal storage disease.1 […] There are three types of GD. Type 1 Gaucher disease (GD1) is the most prevalent form of the disease, accounting for more than 90% of all cases.4 […] GD1 is a pan-ethnic condition, although it does have a higher prevalence in people of Ashkenazi Jewish ancestry.5 […] GD1 affects: 19 in 100,000 within the overall population12 […] ~1 in 600 within the Ashkenazi Jewish population3 […] ~1 in 17 within the Ashkenazi Jewish community that are carriers13 […] an estimated 6,000 individuals in the United States3,14 […] GD1 is genetic and has an autosomal recessive inheritance pattern.3 If both parents are carriers, there is a 50% chance of the child being a carrier, a 25% chance of them having Gaucher disease, and a 25% chance that they will not be affected.3

• #22 Orphanet: Gaucher disease type 1

  https://www.orpha.net/en/disease/detail/77259

  Gaucher disease type 1 is the chronic non-neurological form of Gaucher disease (GD) characterized by organomegaly, bone involvement and cytopenia. […] Prevalence: 1-9 / 100 000. […] It represents around 90% of all cases of GD with an estimated prevalence of 1/100,000 in the general population.

• #23 Orphanet: Gaucher disease type 1

  https://www.orpha.net/en/disease/detail/77259

  Gaucher disease type 1 is the chronic non-neurological form of Gaucher disease (GD) characterized by organomegaly, bone involvement and cytopenia. […] Prevalence: 1-9 / 100 000. […] It represents around 90% of all cases of GD with an estimated prevalence of 1/100,000 in the general population.

• #24 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #25 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #26 Gaucher Disease Type 1 Epidemiology Forecast 2034

  https://www.expertmarketresearch.com/epidemiology-reports/gaucher-disease-type-1-epidemiology-forecast

  According to a 2022 targeted literature review, the incidence of Gaucher disease across all types ranged from 0.45 to 25.0 per 100,000 live births, with the lowest rates observed in the Asia-Pacific region. The incidence of Gaucher disease type 1 ranged from 0.45 to 22.9 per 100,000 live births in Europe and North America. Further, type-specific prevalence estimates per 100,000 population for Gaucher disease type 1 were reported to range from 0.26 to 0.63. […] The prevalence of Gaucher disease type 1 is estimated to be 1 to 9 per 100,000 worldwide, as per Orphanet. […] The incidence of Gaucher disease is influenced by ethnicity, with higher rates observed in specific populations, particularly among those of Ashkenazi Jewish descent, where the estimated frequency for Gaucher disease type 1 is about 1 in 450 births.

• #27 Gaucher’s disease – Wikipedia

  https://en.wikipedia.org/wiki/Gaucher%27s_disease

  The National Gaucher Foundation (United States) states the incidence of Gaucher’s disease is about one in 20,000 live births. Around one in 100 people in the general US population is a carrier for type I Gaucher’s disease, giving a prevalence of one in 40,000. Among Ashkenazi Jews, the rate of carriers is considerably higher, at roughly one in 15. […] Type II Gaucher’s disease shows no particular preference for any ethnic group. […] Type III Gaucher’s disease is especially common in the population of the northern Swedish region of Norrbotten, where the incidence of the disease is one in 50,000.

• #28 Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/gaucher-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Gaucher disease (GD) is one of the most common lysosomal diseases. Type 1 GD (GD1) is the most prevalent type in the United States, Europe, and Israel and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types. There were approximately 20,000 individuals with GD in the United States in the mid-1990s based upon a gene frequency study, two-thirds of whom were Ashkenazi Jews, although fewer reached medical attention. A subsequent survey estimated the standardized birth incidence of GD in the general population to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000. […] In the United States, Europe, and Israel, approximately 90 percent of patients have GD1, which is the nonneuronopathic form. GD1 is the most common type seen in the Ashkenazi Jewish population, although most patients with GD1 are not Jewish. The carrier frequency in the Ashkenazi Jewish population is approximately 1 in 12, and the frequency of disease-associated genotypes is calculated at 1 in 850. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 to 1 in 86,000 live births. […] GD2 (also called acute neuronopathic GD) has an estimated incidence of 1 in 150,000.

• #29 Gaucher Disease | Concise Medical Knowledge

  https://www.lecturio.com/concepts/gaucher-disease/

  Gaucher disease (GD) results from a deficiency in the lysosomal hydrolase beta-glucosidase (glucocerebrosidase). […] Type 1 is the most common, accounting for 90% of GD cases, with an incidence of 1 in 40,000-50,000 live births in the general population. […] More common in the Ashkenazi Jewish population, it is the most prevalent inherited disorder among them, with a carrier frequency of 6%. […] Type 2 is rare, with an incidence of 1 in 150,000 in the general population and no ethnic predilection. […] Type 3 has an incidence of 1 in 200,000 in the general population and accounts for 5% of all patients with GD, being more common in Northern Europe, Egypt, and East Asia.

• #30 Gaucher’s disease – Wikipedia

  https://en.wikipedia.org/wiki/Gaucher%27s_disease

  The National Gaucher Foundation (United States) states the incidence of Gaucher’s disease is about one in 20,000 live births. Around one in 100 people in the general US population is a carrier for type I Gaucher’s disease, giving a prevalence of one in 40,000. Among Ashkenazi Jews, the rate of carriers is considerably higher, at roughly one in 15. […] Type II Gaucher’s disease shows no particular preference for any ethnic group. […] Type III Gaucher’s disease is especially common in the population of the northern Swedish region of Norrbotten, where the incidence of the disease is one in 50,000.

• #31 Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9821068/

  Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD type-specific and overall, published in the last 10 years. […] Across all GD types, incidence estimates ranged 0.4525.0/100,000 live births (16 studies), lowest for Asia-Pacific. Incidence of GD1: 0.4522.9/100,000 live births (Europe and North America) and GD3: 1.36/100,000 live births (Asia-Pacific only). […] GD incidence is associated with ethnicity and is known to be higher in particular populations, such as those of Ashkenazi Jewish descent (estimated at 1 in 450 births for GD type 1) and a population from the Norrbotten and Vsterbotten geographical areas of Sweden (estimated at 1 in 50,000 births for GD type 3); however, GD affects all ethnic groups and prevalence is likely to be underestimated in many countries.

• #32 Gaucher Disease | Concise Medical Knowledge

  https://www.lecturio.com/concepts/gaucher-disease/

  Gaucher disease (GD) results from a deficiency in the lysosomal hydrolase beta-glucosidase (glucocerebrosidase). […] Type 1 is the most common, accounting for 90% of GD cases, with an incidence of 1 in 40,000-50,000 live births in the general population. […] More common in the Ashkenazi Jewish population, it is the most prevalent inherited disorder among them, with a carrier frequency of 6%. […] Type 2 is rare, with an incidence of 1 in 150,000 in the general population and no ethnic predilection. […] Type 3 has an incidence of 1 in 200,000 in the general population and accounts for 5% of all patients with GD, being more common in Northern Europe, Egypt, and East Asia.

• #33 Diagnosis and management of patients with Gaucher disease: an Egyptian expert opinion | Egyptian Journal of Medical Human Genetics | Full Text

  https://jmhg.springeropen.com/articles/10.1186/s43042-024-00552-z

  In a cohort of 216 patients from eight treatment centers in Egypt, the percentage of type 1, type 2, and type 3 GD was reported to be 30.5%, 7.5%, and 62%, respectively. […] Fateen et al tested 5128 suspected cases over a period of 25 years and observed that 882 (17%) had GD. […] The most common disease-causing mutations identified in Egypt were L444P, followed by N370S. […] The characteristics of patients with GD in the Egyptian population are described in Table 1. […] In Egypt, the prevalence of type 3 GD is higher than that of type 1, whereas the prevalence of type 2 disease is rare, and the most common pathogenic variant detected is L444P in heterozygous or homozygous form (47.8%80.0%).

• #34 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Gaucher disease (GD) is a rare lysosomal storage disorder resulting from a deficiency of the lysosomal enzyme glucocerebrosidase caused by biallelic variants in the GBA1 gene. […] While there is no treatment for neuronopathic GD, non-neuronopathic manifestations can be efficiently managed with enzyme replacement therapy or substrate reduction therapy. […] However, many patients with GD experience a lengthy diagnostic odyssey, which can negatively affect their access to care and clinical outcomes. […] This heterogeneity, combined with the molecular complexity of the GBA1 locus, low disease prevalence, and limited knowledge of GD among providers serves as a barrier to early diagnosis of GD. […] Due to the heterogenous nature of the disorder, relatively low prevalence, variation of presentation, and low provider familiarity, patients may experience lengthy diagnostic delays as well as extraneous testing and procedures.

• #35 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Gaucher disease (GD) is a rare lysosomal storage disorder resulting from a deficiency of the lysosomal enzyme glucocerebrosidase caused by biallelic variants in the GBA1 gene. […] While there is no treatment for neuronopathic GD, non-neuronopathic manifestations can be efficiently managed with enzyme replacement therapy or substrate reduction therapy. […] However, many patients with GD experience a lengthy diagnostic odyssey, which can negatively affect their access to care and clinical outcomes. […] This heterogeneity, combined with the molecular complexity of the GBA1 locus, low disease prevalence, and limited knowledge of GD among providers serves as a barrier to early diagnosis of GD. […] Due to the heterogenous nature of the disorder, relatively low prevalence, variation of presentation, and low provider familiarity, patients may experience lengthy diagnostic delays as well as extraneous testing and procedures.

• #36 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Gaucher disease (GD) is a rare lysosomal storage disorder resulting from a deficiency of the lysosomal enzyme glucocerebrosidase caused by biallelic variants in the GBA1 gene. […] While there is no treatment for neuronopathic GD, non-neuronopathic manifestations can be efficiently managed with enzyme replacement therapy or substrate reduction therapy. […] However, many patients with GD experience a lengthy diagnostic odyssey, which can negatively affect their access to care and clinical outcomes. […] This heterogeneity, combined with the molecular complexity of the GBA1 locus, low disease prevalence, and limited knowledge of GD among providers serves as a barrier to early diagnosis of GD. […] Due to the heterogenous nature of the disorder, relatively low prevalence, variation of presentation, and low provider familiarity, patients may experience lengthy diagnostic delays as well as extraneous testing and procedures.

• #37 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  This delay may have long term sequelae, both for the patient and the caregivers, and earlier diagnosis is essential for improving patient outcomes. […] As mentioned, difficulty in diagnosis is often exacerbated by lack of knowledge among providers regarding GD. […] Among hematologists, there remains a lack of awareness of GD, as a study across seven countries found that only 20% of 406 surveyed hematologist oncologists initially considered GD in a patient presenting with common GD manifestations such as anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone pain, instead focusing on leukemia, lymphoma, and multiple myeloma. […] While enzyme replacement therapy and substrate reduction therapy are effective at managing non-neurological manifestations of Gaucher disease, there is a lack of universal standards of care or established management goals.

• #38 Changing clinical manifestations of Gaucher disease in Taiwan | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-023-02895-z

  Gaucher disease (GD) is a lysosomal storage disorder characterized by deficient glucocerebrosidase activity that results from biallelic mutations in the GBA1 gene. […] Newborn screening (NBS) for GD has been available since 2015. […] This study is the first cohort study to provide a comparison of the GD population diagnosed during the pre-NBS and post-NBS eras in Taiwan. […] With the introduction of NBS for GD in 2015, a distinctive representation of the pre-ERT era, post-ERT clinical era, and post-ERT NBS era (or simply the post-NBS era) is apparent in the Gaucher population. […] Since the introduction of NBS for GD in Taiwan, a redistribution in subtypes has been noted, with an increase in individuals with GD2. […] The NBS program is able to advance the age at diagnosis such that better outcomes may be achieved with early intervention. […] However, while ERT is able to reverse hepatosplenomegaly and hematological complications, more treatment options are needed for the management of other symptoms.

• #39 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Limited genotype/phenotype correlations make it difficult to predict which patients may experience the greatest symptom burden and benefit most from treatment. […] Newborn screening (NBS) in the United States is a public health initiative developed and funded at the state level, with wide variation in both screening implementation and disease inclusion. […] The RUSP currently does not include GD or mandate its adoption. […] The benefits of adding GD to the RUSP and state-specific newborn screening programs have been debated given unclear genotype/phenotype correlation, variable age of symptom onset, unreliable biomarkers, and the lack of effective treatment for its neuronopathic manifestations. […] Thus, opinions regarding the utility of NBS are varied. […] In light of these debates and subsequent lack of inclusion in the RUSP, GD is currently part of the newborn screens in only six states Illinois, Missouri, New Jersey, New Mexico, Oregon, and Tennessee in addition to the ongoing ScreenPlus pilot NBS program in New York City. […] The high cost of available therapies is another consideration, as well as the lack of brain penetrant therapies for those affected with the most severe forms of GD.

• #40 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Limited genotype/phenotype correlations make it difficult to predict which patients may experience the greatest symptom burden and benefit most from treatment. […] Newborn screening (NBS) in the United States is a public health initiative developed and funded at the state level, with wide variation in both screening implementation and disease inclusion. […] The RUSP currently does not include GD or mandate its adoption. […] The benefits of adding GD to the RUSP and state-specific newborn screening programs have been debated given unclear genotype/phenotype correlation, variable age of symptom onset, unreliable biomarkers, and the lack of effective treatment for its neuronopathic manifestations. […] Thus, opinions regarding the utility of NBS are varied. […] In light of these debates and subsequent lack of inclusion in the RUSP, GD is currently part of the newborn screens in only six states Illinois, Missouri, New Jersey, New Mexico, Oregon, and Tennessee in addition to the ongoing ScreenPlus pilot NBS program in New York City. […] The high cost of available therapies is another consideration, as well as the lack of brain penetrant therapies for those affected with the most severe forms of GD.

• #41 Monitoring | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/monitoring/

  Laboratory testing for Gaucher disease (GD) should be carried out when a patient presents with signs indicative of the disease, such as unexplained splenomegaly, anemia, or thrombocytopenia.15 Suspicion should be higher when the patient is of Ashkenazi Jewish descent.14,15 […] Some states (including Missouri, New York, Illinois, and Tennessee) currently offer genetic testing to screen newborns for Gaucher disease (GD), with further states currently considering implementation of this testing.4 Check the current status of newborn screening for GD in your state in case your patients have questions or need guidance in this area.

• #42 Changing clinical manifestations of Gaucher disease in Taiwan | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-023-02895-z

  Gaucher disease (GD) is a lysosomal storage disorder characterized by deficient glucocerebrosidase activity that results from biallelic mutations in the GBA1 gene. […] Newborn screening (NBS) for GD has been available since 2015. […] This study is the first cohort study to provide a comparison of the GD population diagnosed during the pre-NBS and post-NBS eras in Taiwan. […] With the introduction of NBS for GD in 2015, a distinctive representation of the pre-ERT era, post-ERT clinical era, and post-ERT NBS era (or simply the post-NBS era) is apparent in the Gaucher population. […] Since the introduction of NBS for GD in Taiwan, a redistribution in subtypes has been noted, with an increase in individuals with GD2. […] The NBS program is able to advance the age at diagnosis such that better outcomes may be achieved with early intervention. […] However, while ERT is able to reverse hepatosplenomegaly and hematological complications, more treatment options are needed for the management of other symptoms.

• #43 Type 1 Gaucher Disease monitoring| Information for patients and families

  https://www.knowgaucherdisease.com/monitoring

  If you have type 1 Gaucher disease, your doctor will ask you to attend regular check-ups to run blood tests, measure your spleen and liver, and perform skeletal scans to monitor the progression of the disease. This usually happens every 324 months and your doctor will guide you. […] If you have type 1 Gaucher disease, know that it is a progressive disease that requires regular monitoring, talk to your doctor about any concerns you may have, and attend regular appointments as advised by them to undergo tests and scans.

• #44 Gaucher disease: Review, epidemio… | Archive ouverte UNIGE

  https://archive-ouverte.unige.ch/unige:85560

  Gaucher disease (GD) is a rare genetic lysosomal disorder which is sometimes complicated by bone events (BEs) such as avascular necrosis, bone infarct or pathological fracture. […] In 2009, we established a French Gaucher Disease Registry (FGDR). An epidemiological analysis of all cases of GD in France identified 562 patients, registering 378 with follow-up (including 90 deaths and 46 monoclonal gammopathies) and 283 undergoing follow-up. […] In 2009, a worldwide shortage in the supply of imiglucerase led to treatment modifications or interruptions for patients with GD type 1. We describe the shortage’s impact on therapeutic management and the disease’s course in French patients. […] Further studies should continue to use biomarker modelling with the patient registry in order to try to predict BE and other complications before treatment.

• #45 In-depth phenotyping for clinical stratification of Gaucher disease | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-02034-6

  The GAUCHERITE cohort, which comprises 85% of all patients known to have Gaucher disease in the United Kingdom, represents an independent, data-rich platform to study the epidemiology and course of this heterogeneous disorder. […] We show that the database is a source of information that allows clinical effectiveness and appropriateness of care to be investigated in real-world clinical practice; the data can moreover be explored in depth by stratifying patients according to potentially divergent treatment effects.

• #46 Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review

  https://www.mdpi.com/2077-0383/12/1/85

  Newborn screening programs were developed for several LSDs, aiming to achieve earlier disease detection with a view to improving long-term patient outcomes. […] The objective of this targeted review was to provide a qualitative synthesis of global GD incidence and prevalence estimates by region, overall, and by disease type, published in the last 10 years. […] The synthesis of GD incidence and prevalence estimates by region in this review highlighted significant data gaps. […] The availability of epidemiologic data on GD is likely to reflect accessibility to healthcare, because the diagnosis of GD requires the use of techniques that are both invasive and resource intensive. […] Population estimates at specific time points can provide a useful benchmark from which to monitor future changes in GD incidence and prevalence and for tracking the emergence of new genetic variants associated with GD identified by genetic profiling.

• #47 SciELO Brazil – Difficulties in the Diagnosis of Gaucher Disease in a Low-Income Country: A Case Report from Mozambique Difficulties in the Diagnosis of Gaucher Disease in a Low-Income Country: A Case Report from Mozambique

  https://www.scielo.br/j/jiems/a/TxyC5X5TTMJMFrFZJZ4fC4D/

  Gaucher disease (GD) is one of the common lysosomal storage disorder (LSD) with an estimated frequency of one in 40,000 newborns globally. […] Mozambique is a low-income country that ranks in the bottom 10 positions of the global human development index (180th) […] The introduction of a diagnosis and treatment protocol for GD in the national health system is not feasible at this moment due to the high cost to keep these patients under follow-up and treatment due to underfunding of the health system. […] The patients diagnosis led to suspicion that her sister who had a similar initial presentation and died at the age of 5 after splenectomy surgery also had GD. […] The suspicion of a genetic condition only arose with the second similar case in the family. […] There were delays in her referral and evaluation that reflect weaknesses in symptom recognition and intra-hospital communication and coordination of care. […] Mozambique is a low-income country, with most of the population depending on healthcare provided by the National Health System, which is largely underfunded.

• #48 Incidence of Pulmonary and Respiratory Conditions in Gaucher Disease from 2000 to 2020: A Multi-institutional Cohort Study | In Vivo

  https://iv.iiarjournals.org/content/37/5/2276

  We conducted a global cohort study analyzing over 15,000 patients with GD to determine how the epidemiology of this rare disorder has evolved over the past 20 years. We found significantly higher incidence and prevalence rates in the latter period, likely due to improved disease recognition and access to treatment. Early diagnosis and optimized management of GD are crucial to prevent morbidity and mortality, though additional research is still needed to fully understand its societal burden. The prevalence of GD increased from 0.017% in 2000 to 0.036% in 2020, while incidence rose from 0.006% to 0.012% over the same period. Pulmonary and respiratory disease are major causes of morbidity and mortality in GD. Up to 100% of GD patients develop lung pathology over their lifetime, and 6.2% die from pulmonary complications. Despite this substantial burden, limited data exist on incidence and prevalence of respiratory manifestations.

• #49 Incidence of Pulmonary and Respiratory Conditions in Gaucher Disease from 2000 to 2020: A Multi-institutional Cohort Study | In Vivo

  https://iv.iiarjournals.org/content/37/5/2276

  We conducted a global cohort study analyzing over 15,000 patients with GD to determine how the epidemiology of this rare disorder has evolved over the past 20 years. We found significantly higher incidence and prevalence rates in the latter period, likely due to improved disease recognition and access to treatment. Early diagnosis and optimized management of GD are crucial to prevent morbidity and mortality, though additional research is still needed to fully understand its societal burden. The prevalence of GD increased from 0.017% in 2000 to 0.036% in 2020, while incidence rose from 0.006% to 0.012% over the same period. Pulmonary and respiratory disease are major causes of morbidity and mortality in GD. Up to 100% of GD patients develop lung pathology over their lifetime, and 6.2% die from pulmonary complications. Despite this substantial burden, limited data exist on incidence and prevalence of respiratory manifestations.

• #50 Incidence of Pulmonary and Respiratory Conditions in Gaucher Disease from 2000 to 2020: A Multi-institutional Cohort Study | In Vivo

  https://iv.iiarjournals.org/content/37/5/2276

  We conducted a global cohort study analyzing over 15,000 patients with GD to determine how the epidemiology of this rare disorder has evolved over the past 20 years. We found significantly higher incidence and prevalence rates in the latter period, likely due to improved disease recognition and access to treatment. Early diagnosis and optimized management of GD are crucial to prevent morbidity and mortality, though additional research is still needed to fully understand its societal burden. The prevalence of GD increased from 0.017% in 2000 to 0.036% in 2020, while incidence rose from 0.006% to 0.012% over the same period. Pulmonary and respiratory disease are major causes of morbidity and mortality in GD. Up to 100% of GD patients develop lung pathology over their lifetime, and 6.2% die from pulmonary complications. Despite this substantial burden, limited data exist on incidence and prevalence of respiratory manifestations.

• #51 Incidence of Pulmonary and Respiratory Conditions in Gaucher Disease from 2000 to 2020: A Multi-institutional Cohort Study | In Vivo

  https://iv.iiarjournals.org/content/37/5/2276

  We conducted a global cohort study analyzing over 15,000 patients with GD to determine how the epidemiology of this rare disorder has evolved over the past 20 years. We found significantly higher incidence and prevalence rates in the latter period, likely due to improved disease recognition and access to treatment. Early diagnosis and optimized management of GD are crucial to prevent morbidity and mortality, though additional research is still needed to fully understand its societal burden. The prevalence of GD increased from 0.017% in 2000 to 0.036% in 2020, while incidence rose from 0.006% to 0.012% over the same period. Pulmonary and respiratory disease are major causes of morbidity and mortality in GD. Up to 100% of GD patients develop lung pathology over their lifetime, and 6.2% die from pulmonary complications. Despite this substantial burden, limited data exist on incidence and prevalence of respiratory manifestations.

• #52 Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review

  https://www.mdpi.com/2077-0383/12/1/85

  Newborn screening programs were developed for several LSDs, aiming to achieve earlier disease detection with a view to improving long-term patient outcomes. […] The objective of this targeted review was to provide a qualitative synthesis of global GD incidence and prevalence estimates by region, overall, and by disease type, published in the last 10 years. […] The synthesis of GD incidence and prevalence estimates by region in this review highlighted significant data gaps. […] The availability of epidemiologic data on GD is likely to reflect accessibility to healthcare, because the diagnosis of GD requires the use of techniques that are both invasive and resource intensive. […] Population estimates at specific time points can provide a useful benchmark from which to monitor future changes in GD incidence and prevalence and for tracking the emergence of new genetic variants associated with GD identified by genetic profiling.

• #53 Disease Overview – Gaucher Disease

  https://gaucherdiseaseplatform.org/disease-overview/

  Gauchers disease is a pan-ethnic disorder that has had major focus in developed countries with populations of European origin. […] The overall frequency of Gauchers disease variants is about one in 40,000 to one in 60,000 livebirths in the general population. However, there is a higher frequency of Gauchers disease type 1 in the Ashkenazi Jews, about one in 800 livebirths. This has led to characterisation of disease phenotypes mainly on the basis of that population. […] However, the growing recognition of substantial populations with type 1 disease in Asia, South America, the Indian subcontinent, and other demographic areas is broadening our appreciation of the range of phenotypes in this variant. […] Similarly, with the broader recognition of types 2 and 3, widespread variation and range of involvement from early onset has become increasingly evident. […] The general frequencies of any of the variants in large populations of China, India, Indonesia, the Middle East, or Africa are unknown.

• #54 An Overview of Gaucher Disease | Scilit

  https://www.scilit.com/publications/e3e60e254ba9b9be6e7306aafc0ca640

  Background: Gaucher disease (GD) is a rare autosomal recessive disorder caused by mutations in the GBA1 gene that lead to a deficiency in the glucocerebrosidase gene. This deficiency results in the accumulation of glucocerebrosides in macrophages, primarily affecting the liver, spleen, and bone marrow. Focusing on the Mexican population, this study aims to review GD’s epidemiology, clinical manifestations, and treatment options to enhance early diagnosis and optimize treatment outcomes. […] Continued research is required to enhance therapeutic approaches for the neuropathic types and better understand the disease’s epidemiology in Mexico.

• #55 Gaucher Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  https://www.globaldata.com/store/report/gaucher-disease-market-opportunity-analysis/

  The Gaucher Disease market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued $1.22 billion in 2022. A steady growth is anticipated at a CAGR of less than 1% from 2022 to 2032. The Gaucher Disease market research report offers an overview of Gaucher Disease, including its epidemiology, symptoms, diagnosis, and disease management. […] The key countries in the Gaucher Disease market are the US, 5EU, and Israel. In 2022, the US dominated the total Gaucher Disease market share. The dominance of the US within the 7MM is due to its larger GD population and higher drug prices. […] The combination of improved physician awareness and decreased patient reluctance to become involved in diagnosis and treatment, especially in the Ashkenazi Jewish population are slightly contributing to the market growth. The other minor market growth factors are increased inclusion of GD in NBS panels and wider adoption of NBS. […] The key drugs in the Gaucher Disease market are ERTs, SRTs, and PCs. In 2022, ERTs was the leading drug class in the Gaucher Disease market. The current management of Type 1 GD relies on marketed ERT and SRT. […] The key sponsors in the Gaucher Disease market are Sanofi and Takeda.

• #56 Gaucher Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  https://www.globaldata.com/store/report/gaucher-disease-market-opportunity-analysis/

  The Gaucher Disease market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued $1.22 billion in 2022. A steady growth is anticipated at a CAGR of less than 1% from 2022 to 2032. The Gaucher Disease market research report offers an overview of Gaucher Disease, including its epidemiology, symptoms, diagnosis, and disease management. […] The key countries in the Gaucher Disease market are the US, 5EU, and Israel. In 2022, the US dominated the total Gaucher Disease market share. The dominance of the US within the 7MM is due to its larger GD population and higher drug prices. […] The combination of improved physician awareness and decreased patient reluctance to become involved in diagnosis and treatment, especially in the Ashkenazi Jewish population are slightly contributing to the market growth. The other minor market growth factors are increased inclusion of GD in NBS panels and wider adoption of NBS. […] The key drugs in the Gaucher Disease market are ERTs, SRTs, and PCs. In 2022, ERTs was the leading drug class in the Gaucher Disease market. The current management of Type 1 GD relies on marketed ERT and SRT. […] The key sponsors in the Gaucher Disease market are Sanofi and Takeda.

• #57 Gaucher Disease Market Research Reports, Industry Insights – GlobalData

  https://www.globaldata.com/store/industry/gaucher-disease-market/

  Discover unique market-leading data and insights into the Gaucher Disease market. From the latest Gaucher Disease industry reports and analysis to comprehensive market growth forecasts, trends and research. […] Gaucher Disease Market Report Overview The Gaucher Disease market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued $1.22 billion in 2022. A steady growth is anticipated at a CAGR of less than 1% from 2022 to 2032. The major driver for this growth will be improved diagnostic approaches, the launch of Sanofis SRT venglustat malate, as well as the introduction of eliglustat tartrate generics. […] A total of 151 Gaucher Disease clinical trials were conducted as of May 2024. The Gaucher Disease clinical trial report provides a comprehensive understanding of the Gaucher Disease clinical trial scenario across regions, and countries (G7 E7), along with insights into the various phases, trial status, and end points status.

• #58 Gaucher Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  https://www.globaldata.com/store/report/gaucher-disease-market-opportunity-analysis/

  The Gaucher Disease market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued $1.22 billion in 2022. A steady growth is anticipated at a CAGR of less than 1% from 2022 to 2032. The Gaucher Disease market research report offers an overview of Gaucher Disease, including its epidemiology, symptoms, diagnosis, and disease management. […] The key countries in the Gaucher Disease market are the US, 5EU, and Israel. In 2022, the US dominated the total Gaucher Disease market share. The dominance of the US within the 7MM is due to its larger GD population and higher drug prices. […] The combination of improved physician awareness and decreased patient reluctance to become involved in diagnosis and treatment, especially in the Ashkenazi Jewish population are slightly contributing to the market growth. The other minor market growth factors are increased inclusion of GD in NBS panels and wider adoption of NBS. […] The key drugs in the Gaucher Disease market are ERTs, SRTs, and PCs. In 2022, ERTs was the leading drug class in the Gaucher Disease market. The current management of Type 1 GD relies on marketed ERT and SRT. […] The key sponsors in the Gaucher Disease market are Sanofi and Takeda.

Zobacz więcej